A Phase 1, Open Label Study to evaluate the safety Pharmacokinetic, Pharmacodynamic and clinical activity of PF-06863135, A B-Cell Maturation Antigen (BCMA)- CD3 Bispecifi Antibody In Patient

Administered By

Awarded By

Contributors

Start/End

  • March 7, 2018 - April 30, 2023